

EU-Rahmenprogramm für Forschung und Innovation Horizont Europa 2021 bis 2027

Fördermöglichkeiten und Rahmenbedingungen für Projekte in Cluster 1: Gesundheit

Hicham Abghay, Kristin Dallinger
Steinbeis Europa Zentrum


Webseminar
28.04.2021

Agenda

- Allgemeine Einführung in Horizont Europa
- Allgemeine Einführung in Cluster 1
- Diskussion:
 - Fragen von den TeilnehmerInnen
 - Impulse zu spezifischen Themen → gegebenenfalls **Fokus** auf ausgewählten Thematiken und Rahmenbedingungen

Technische Hinweise

- **Willkommen im Schnellzug nach Brüssel:**
- **Sie sitzen im Ruhebereich:** Bitte schalten Sie Ihr Mikrofon und Ihre Kamera aus.
- **Q&A:** Fragen können im Chat gestellt werden.
Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.
- **Kennenlernen:** Nehmen Sie in an unserer Live-Umfrage teil >> Was ist Ihre aktuelle Position?



oder mit dem Link im Chat:

<https://www.menti.com/k9zd1ycyoy>

Hinweis: Dieses Webinar wird für interne Zwecke aufgezeichnet.

Das Steinbeis Europa Zentrum

Wofür wir uns engagieren:

- Unternehmen und Organisationen in ihrer Zukunftsfähigkeit stärken
- Unternehmen, Forschungseinrichtungen, Hochschulen und öffentliche Einrichtungen mit innovativen Partnern in Europa vernetzen
- Europäische Kooperationen in Forschung und Technologie stimulieren und begleiten
- Europäische Förderprogramme bekannt machen und nutzen
- 75 Mitarbeiter an zwei Standorten (Stuttgart, Karlsruhe)
- Interdisziplinär, Mitarbeiter aus 16 Ländern



INNOVATIONSFINANZIERUNG



INNOVATIONSMANAGEMENT



INTERNATIONALISIERUNG & MARKTZUGANG



INNOVATIONSPOLITIK



VERANSTALTUNGEN & QUALIFIZIERUNG



Das Steinbeis Europa Zentrum

- **Beratungsstelle für KMU für Horizont Europa** in Baden-Württemberg im Auftrag des Europabeauftragten der Ministerin für Wirtschaft, Arbeit und Wohnungsbau
- **EU-Beratungsstelle für die Hochschulen für angewandte Wissenschaften und die Dualen Hochschulen** in Baden-Württemberg im Auftrag des Ministeriums für Wissenschaft, Forschung und Kunst
- Teil des **Enterprise Europe Network** mit 600 Partnern in über 60 Ländern



Baden-Württemberg

MINISTERIUM FÜR WIRTSCHAFT, ARBEIT UND WOHNUNGSBAU




Baden-Württemberg

MINISTERIUM FÜR WISSENSCHAFT, FORSCHUNG UND KUNST



Das Enterprise Europe Network

- Besteht seit 2008
- Von der Europäischen Kommission finanziert
- Ca. 600 Mitgliedsorganisationen
 - in über 60 Ländern
 - in der gesamten EU und **darüber hinaus**
- Mitgliedsorganisationen: Industrie- und Handelskammern, Technologiezentren, Hochschulen und Wirtschaftsförderungsagenturen



Netzwerkaufbau und Partnersuche



- **Enterprise Europe Network** geförderte KMU-Partnersuche für Verbundprojekte – Sprechen Sie uns an!
- **Virtuelle Kooperationsbörsen:**
 - [EU Brokerage Event](#) am 11. Mai
 - [Matchmaking event at BIONNALE](#) am 12. Mai
 - [eHealth Match](#) am 18. – 20. Mai
 - [TechInnovation](#) vom 28. – 30. September
 - [Pharma, cosmetic and biotech brokerage event at Farmaforum](#) am 4. November (Präsenzveranstaltung)
- **Trainings von S2i**
 - [Das Projekt läuft an – in der Projektadministration durchblicken](#) vom 22. – 23. September (virtuell)
 - [Hilfe, mein EU-Projekt wurde genehmigt - die Klaviatur des Projektkoordinators](#) am 7. Dezember (Präsenzveranstaltung)

BMBF-Förderung: FH-Europa ([link](#)) ([FAQ](#))

- Für
 - **Die Erstellung von Forschungsanträgen**, die bis zum 31. Dezember 2027 bei der Europäischen Kommission eingereicht werden: im Rahmen von „Horizont Europa“ aber auch von anderen europäischen, multinationalen Forschungsförderungsprogrammen, vorzugsweise „Green Deal“ sowie „EUREKA“.
 - **Die Bildung und Verstetigung von Netzwerken mit potenziellen Projektpartnern aus dem europäischen Ausland sowie für Forschungs-/Forscheraustausche im EU-Ausland (gegebenenfalls im Rahmen von internationalen Promotionen)**, mit dem Ziel gemeinsame Antragstellungen zu fördern. Diese zu beantragenden Maßnahmen sind nicht zwingend an den gewählten Call bzw. an dessen Einreichungsfristen gebunden.
- **Laufzeit:** maximal 12 Monate; Endet mit der Einreichung des zu erarbeitenden Antrags. Nur wenn auch zusätzliche Arbeiten zu netzwerkbildenden Maßnahmen durchgeführt werden, endet die Projektlaufzeit mit dem Ende derselben. Die Vorhaben müssen spätestens am 31. Dezember 2027 beendet sein.
- **Pro FH/HAW sind maximal zwei zeitgleich laufende Projekte zulässig.**

BMBF-Förderung: Stärkung deutscher Koordinationen in den thematischen Cluster vom 2. Pfeiler in Horizont Europa ([link](#)) ([FAQ](#))

- Für geplante deutsche koordinierende Hochschulen, Forschungseinrichtungen, Kommunen und KMU
 - (Antragstellung) Maßnahmen zur Vorbereitung und Erstellung von Anträgen
 - ✓ in den thematischen Clustern im 2. Pfeiler „Globale Herausforderungen und industrielle Wettbewerbsfähigkeit Europas“
 - ✓ für Verbundprojekte innerhalb Europäischer Partnerschaften, die dem zweiten Pfeiler von Horizont Europa thematisch zuzuordnen sind
 - (Konsortiums-Aufbau) Einzelvorhaben für die Sondierung, den Auf- und Ausbau von themenspezifischen Konsortien und die Zusammenarbeit an der Entwicklung der Anträge
- ➔ unter anderem Reisekosten, die der Vernetzung und Zusammenarbeit mit potenziellen Konsortialpartnern dienen, die Umsetzung von Workshops sowie Personalkosten zur Koordinierung der Zusammenarbeit
- **Nicht gefördert:** Coordination and Support Actions, Maßnahmen der Individualförderung und Preise.
- **Förderung:** in der Regel maximal 50.000 Euro über maximal 12 Monate.
- **Einreichung:** 31.05.2021, dann alle Jahre am 31.01, 31.05 und 30.09 bis zum 30.09.2023.

HORIZON EUROPE CLUSTER HEALTH

Struktur, Aufbau und Logik

Informationen sind vorläufig und unverbindlich!!

Horizon Europe - GESUNDHEITSFORSCHUNG

—

Eckdaten

Live Umfrage:


Waren Sie bereits an einer Antragstellung für ein
EU-Projekt (FP7, H2020) beteiligt?



oder mit dem Link im Chat:

<https://www.menti.com/k9zd1ycyoy>

Specific objectives of the Programme



Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

HEurope Ausschreibungen Arbeitsprogramm Gesundheit 2021-2022 (Entwurf)

Horizon Europe Rahmenprogramm für Forschung und Innovation 2021-2027 EUR 95,5 Mrd.

Spezifisches Programm: Globale Herausforderungen 2021-2027

Globale Herausforderung: Cluster 1 Gesundheit

EUR 7.5 Mrd.

Arbeitsprogramm 2021-2022

EUR 1.9 Mrd

Horizon 2020 vs. Horizon Europe

Kontinuität?

- Transdisziplinarität und transregionale Ausrichtung – EU Mehrwert
- Unterschiedliche Maßnahmen und Instrumente
- Sowohl Bottom-up als auch Top-down Aktionen

Dennoch...

- Kurze Anträge
- Mehr Betonung auf „Impacts“ and „Outcomes“
- Gender Equality Plan* (spezielles Webseminar für HAW's **DATUM!!!!**)
- Gemeinsame Gestaltung durch GD. Forschung und Innovation sowie Gesundheit und Lebensmittelsicherheit
- Gesundheitspolitik und politische Prioritäten als zentrale Ideengeber für die Aufrufe und Themen
- Prävention umfasst Themen wie: Life Style, Umwelteinflüsse, Ernährung etc...
- IKT Themen bzw. KETs wurden integriert in den Aufrufen (digital health, AI, etc...)

Horizon Europe - GESUNDHEITSFORSCHUNG

—

Eckdaten

Live Umfrage:

Aus welchen Gründen würden Sie an EU-Projekt teilnehmen?



oder mit dem Link im Chat:

<https://www.menti.com/k9zd1ycyoy>

Expected Impact	Impact Areas
1. Staying healthy in a rapidly changing society	<ul style="list-style-type: none"> ➤ healthier lifestyles & behaviours, healthier environments, improved evidence-based health policies effective solutions ➤ better understanding of specific health & care needs throughout the life course, incl. age-specific & sex/gender-specific needs ➤ develop innovative services, guidelines and digital solution for people & communities ➤ availability of real-world health data
2. Living and working in a health-promoting environment	<ul style="list-style-type: none"> ➤ Better understanding of environmental, occupational, social and economic determinants of health in living and working environments ➤ identify and assess the risks and benefits for health, to enable health promoting and disease preventive actions provide solid evidence ➤ stimulate uptake into environmental, occupational, social, economic, fiscal and health policies ➤ collaborations across sectors and with other clusters
3. Tackling diseases and reducing disease burden	<ul style="list-style-type: none"> ➤ infectious, poverty-related, neglected diseases, non-communicable & rare diseases ➤ reduce the disease burden on patients ➤ better understanding of diseases ➤ improve existing prevention strategies to create tangible impacts ➤ better ability & preparedness to manage epidemic outbreaks ➤ new prevention, public health interventions, diagnostics, vaccines, therapies, alternatives to antibiotics

Impact Areas

Expected Impact	Impact Areas Expected
<p>4. Ensuring access to innovative, sustainable and high-quality health care</p>	<ul style="list-style-type: none"> ➤ equal access to innovative, sustainable and high-quality health care ➤ development and uptake of safe, cost-effective & people-centred solutions ➤ focus on population health, health systems resilience, and evidence-based health policies ➤ innovative solutions in various dimensions (governance, financing, generation of human and physical resources, patient empowerment etc.)
<p>5. Unlocking the full potential of new tools, technologies and digital solutions for a healthy society</p>	<ul style="list-style-type: none"> ➤ New tools, health technologies & digital solutions for biomedical research, prevention, diagnosis, therapy & monitoring tailored to specific needs ➤ safety, effectiveness, inter-operability, accessibility, appropriateness, affordability, sustainability ➤ translate innovations into health policies & practice ➤ multidisciplinary, cross-sector cooperation with key stakeholders (patients, care providers, researchers, regulatory bodies, policy-makers, funders) ➤ AI for analysis of health data advance care
<p>6. Maintaining an innovative, sustainable and globally competitive health-related industry</p>	<ul style="list-style-type: none"> ➤ Need for cross-sectorial research and innovation (integrating medical technologies, pharmaceuticals, biotechnologies, digital health and eHealth technologies) ➤ Supporting the standardisation policy, driving innovation from the demand side and providing evidence and guidelines for stakeholders and regulators to ensure take-up of innovations ➤ Support to studies for health assessment procedures, clinical performance demonstration, quality assurance schemes and standardisation

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

Förderinstrumente

Research and Innovation Actions (RIA)	Innovation Actions (IA)	Coordination and Support Action (CSA)
<ul style="list-style-type: none"> • Aktivitäten, die darauf abzielen, neue Kenntnisse zu gewinnen und/oder die Durchführbarkeit von neuen oder verbesserten Technologien, Produkten, Prozessen, Dienstleistungen oder Lösungen zu untersuchen. • Grundlagen- und Angewandte Forschung, Technologieentwicklungen und -integration, Prüfung und Validierung mit Prototypenerstellung in kleinem Umfang im Labor oder dem Einsatz in einer simulierten Umgebung. 	<ul style="list-style-type: none"> • Aktivitäten, die direkt darauf abzielen, Pläne und Ausgestaltungen oder Designs für neue, veränderte oder verbesserte Produkte, Prozesse oder Dienstleistungen zu entwickeln. • Dies beinhaltet die Anfertigung von Prototypen, Prüfungen, Demonstrationen, Pilotaktionen, Produktvalidierung in großem Umfang und Marktumsetzung. 	<ul style="list-style-type: none"> • Begleitmaßnahmen, wie Standardisierung, Verbreitung, Bewusstseinsförderung und Kommunikation sowie Vernetzung, Koordination oder weiteren Dienstleistungen, Politikdialogen und wechselseitiges Lernen durch Übungen und Studien, einschließlich Projektstudien zu neuer Infrastruktur • Sie können auch ergänzende Aktivitäten von Strategieplanung, Vernetzungen und Koordination zwischen Programmen verschiedener Länder beinhalten.
<p style="text-align: center;">100% Förderquote</p>	<p style="text-align: center;">70% Förderquote</p>	<p style="text-align: center;">100% Förderquote</p>

HORIZON EUROPE CLUSTER HEALTH

Ausschreibungen

Projekttyp **Research & Innovation Actions**

Abgabetermin 21.09.2021

Informationen sind vorläufig und unverbindlich!!

Ausschreibungen |

RIA - 21.09.2021

Call by Destination	Call No.	Type	Total Budget	No. of Projects
Destination 1 Staying healthy in a rapidly changing society				
Towards a molecular and neurobiological understanding of mental health and mental illness for the benefit of citizens and patients	HORIZON-HLTH-2021-STAYHLTH-01-02	RIA	60 M€	6
Destination 2 - Living & working in a health-promoting environment				
Exposure to electromagnetic fields (EMF) and health	HORIZON-HLTH-2021-ENVHLTH-02-01	RIA	30 M€	4
Indoor air quality and health	HORIZON-HLTH-2021-ENVHLTH-02-02	RIA	40 M€	5
Health impacts of climate change, costs and benefits of action and inaction	HORIZON-HLTH-2021-ENVHLTH-02-03	RIA	60 M€	6

Ausschreibungen |

RIA - 21.09.2021

Call by Destination	Call No.	Type	Total Budget	No. of Projects
Destination 3 – Tackling diseases & reducing disease burden				
Improved supportive, palliative , survivorship and end-of-life care of cancer patients	HORIZON-HLTH-2021-DISEASE-04-01	RIA	50 M€	8
Building a European innovation platform for the repurposing of medicinal products	HORIZON-HLTH-2021-DISEASE-04-02	RIA	50 M€	2
Innovative approaches to enhance poverty related diseases research in sub-Saharan Africa	HORIZON-HLTH-2021-DISEASE-04-03	RIA	40 M€	5
Clinical validation of artificial intelligence (AI) solutions for treatment and care	HORIZON-HLTH-2021-DISEASE-04-04	RIA	60 M€	10
Personalised medicine + infectious diseases: understanding individual host response to viruses (e.g. SARS-CoV-2)	HORIZON-HLTH-2021-DISEASE-04-07	RIA	60 M€	9
Destination 4 – Ensuring access to innovative, sustainable & high-quality Healthcare				
Enhancing quality of care and patient safety	HORIZON-HLTH-2021-CARE-05-01	RIA	25 M€	5
Data-driven decision-support tools for better health care delivery and policy-making with a focus on cancer	HORIZON-HLTH-2021-CARE-05-02	RIA	40 M€	4

Call by Destination	Call No.	Type	Total Budget	No. of Projects
Destination 5 – Unlocking the full potential of new tools, technologies and digital solutions for a healthy society				
Smart medical devices and their surgical implantation for use in resource-constrained settings	HORIZON-HLTH-2021-TOOL-06-01	IA	25 M€	4
Next generation advanced therapies to treat highly prevalent and high burden diseases with unmet medical needs	HORIZON-HLTH-2021-TOOL-06-02	RIA	60 M€	10
Innovative tools for use and re-use of health data (in part. of electronic health records and/or patient registries)	HORIZON-HLTH-2021-TOOL-06-03	RIA	30 M€	4
Destination 6 – Maintaining an innovative, sustainable and globally competitive health industry				
Green pharmaceuticals	HORIZON-HLTH-2021-IND-07-01	RIA	40 M€	5

HORIZON EUROPE CLUSTER HEALTH

—

DESTINATION 1

Staying healthy in a rapidly changing society

#STAYHLTH

STAYHLTH-01-02: Towards a molecular and neurological understanding of mental health and mental illness for the benefit of citizens and patients

Scope (several of the following):

- **Interaction of genetic, epigenetic, environmental risk and resilience factors** during transition towards mental illness
- **Predictive models**
(large European cohort, psychiatric disorders)
- **Identification + Validation of biomarkers**
(different types, combinations)
- **Biomarker discovery with supportive disciplines**
(neuropsychology, -physiology, -immunology, -endocrinology, -imaging, electrophysiological monitoring, e-health/m-health, -omics, optogenetics, nanomedicine, stem cell biology)
- **Discovery of new disease pathway, drug targets, prevention strategies**

Conditions

- Diff. stage of innovation cycle
 - basic
 - translational
 - real-world setting
- Strong involvement of
 - End-users
 - Patients
 - Citizen
- Differences due to
 - Gender
 - Age
- Multidisciplinary approaches

HORIZON EUROPE CLUSTER HEALTH

—

DESTINATION 2

Living & working in a health-promoting environment

#EVNHLTH

ENVHLTH-02-01: Exposure to electromagnetic fields (EMF) and health

Scope (all of the following):

Forward-looking information on potential hazards and risks of existing and emerging EMF exposures through innovative monitoring techniques, experimental evidence and modelling

- **Innovative technologies** for exposures monitoring
- Establishment of potentially new **exposure patterns**
- **In vitro/vivo experiments** on local/systemic health impacts
- Data on level + duration of exposures + potential effects, incl. potential mechanisms
- Proposal of new **quality criteria** and standards (CEN/ISO 32) for analytical methodologies assessing human health impact due to exposure to EMF
- **Case studies on solutions for exposure reduction**
- Proposal + testing efficient communication methods/tools for **engaging citizens** in preventive actions

Conditions

- Networking and Sharing of best practices
- FAIR data provision
 - Findability,
 - Accessibility,
 - Interoperability
 - Reusability
- Aspects
 - Gender, Age, Regional variations, Socio-economics, Culture
 - Living/Working environments
 - General population and vulnerable groups

ENVHLTH-02-02: Indoor air quality and health

Scope (all of the following):

- Identification + characterisation of **sources and routes of exposure and dispersion** of chem./bio. indoor air pollution
- Identification of differences and **modes of interaction between indoor and outdoor air quality**
- Development of **technologies** enabling cost-effective monitoring of indoor air quality
- Development of **effect-based test systems** (synergistic effects)
- Identification of **body burdens** resulting from multipollutant (real-life scenario) indoor exposures and associated health effects
- **Dose-response studies** to facilitate **quality standard setting**
- Development of cost-effective, environment-friendly + scalable **technologies** to improve indoor air quality to reduce disease burdens
- Guidelines for interventions, supporting disease prevention
- **User-friendly databases** on exposures, sources and risk factors.

Conditions

- Networking and Sharing of best practices
- FAIR data provision
 - Findability,
 - Accessibility,
 - Interoperability
 - Reusability
- Aspects
 - Gender, Regional variations, Culture, Socioeconomics
 - Vulnerable groups, Sensitive life stages
 - Sectors (construction, transport)

ENVHLTH-02-03: Health impacts of climate change, costs and benefits of action and inaction

Scope (1 of the two topics):

- **Innovative surveillance tools** (e.g. big data, AI, remote sensing, citizen science, biomarkers of exposure or virulence) for (1) timely response to emerging threats (2) design, monitoring and evaluation of interventions.

Area 1

changes in environmental pollution impacts on interrelated ecosystems influence on human health

(all of the following topics):

- **Indicators & monitoring mechanisms** to assess the health-relevant outcomes of climate policies
- **Predictive models** and early warning systems for exposure
- **Tools** for health impact and **cost-benefit** assessment of climate-change adaptation and mitigation measures;
- **Demonstration** of the validity of tools/methods in case studies;
- Societal implications of climate change on health systems
- **Training materials** on climate change health impacts
- **Data** on pos./neg. health impacts of climate change

Area 2

emergence/spread of zoonotic pathogens using Eco-health + One Health approaches.

Conditions

- International cooperation supporting climate policies
- Networking and Sharing of best practices
- Use of data / products from the Copernicus programme,
- FAIR data provision
- Aspects
 - Gender, Age, Regional variations, Culture, Socioeconomics

HORIZON EUROPE CLUSTER HEALTH

—

DESTINATION 3

Tackling diseases and reducing disease burdens

#DISEASE

DISEASE-04-01: Improved supportive, palliative, survivorship and end-of-life care of cancer patients

Scope (all of the following activities):

- Demonstrate the **(cost-) effectiveness** of newly proposed or specifically adapted **(non-)pharmacological interventions** (late long-term side effects of cancer treatments, legal / ethical aspects).
- Prove the **feasibility of integrating** the proposed interventions in current pain management, palliative, supportive, survivorship and/or end-of-life care regimes and healthcare systems **across Europe**.
- Analyse relationships between sex, gender, age, disabilities & socio-economic **factors affecting health equity** of proposed interventions.
- Analyse **barriers and opportunities** for timely social inclusion of cancer patients.
- Provide **guidelines for patient-centred communication & policy recommendations** for pain management & psychological support of cancer patients afflicted by long-term side effects of treatments.

Conditions

- Randomised clinical trials and observational studies, (children or adults or elderly)
- Involve Social Sciences and Humanities experts
- Patient-centres approach (social innovation)
- Networking and Sharing of best practices

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

DISEASE-04-02: Building a European innovation platform for the repurposing of medicinal products

Scope (all of the following activities):

- **Set up a platform** supporting an innovative repurposing model with a (harmonized + sustainable, attracting investments, global lead).
- Provide **robust and transparent selection mechanisms** for prioritising already approved medicinal products or investigational products for repurposing
- Leverage, pool and share existing **high quality data assets** in EU-repurposing landscape (pharmacogenomics, in silico, and AI approaches)
- Resolve the **fragmentation** and lack of ownership of the repurposing approach for efficient exploitation (networking of existing projects).
- **Devise and test** as a European innovation platform

Conditions

- Particular attention should be given to already EC funded repurposing projects and regulators initiatives in the field.
- Networking
- 25 Mio € / project

DISEASE-04-03: Innovative approaches to enhance poverty related diseases research in sub-Saharan Africa

Scope (all of the following topics):

- Need to further support research on the major infectious disease threats facing sub-Saharan Africa: product development and use of new, innovative approaches and emerging technologies
- **Develop smart highly innovative health technologies/ concepts to prevent, treat or diagnose PRD**
- Implement min. 1 medium-scale clinical trial (proof-of-concept)
- Increase collaboration with investors, involve pharmaceutical companies and SMEs
- Develop solutions that are easily integrated or linked to existing electronic/digital systems used in patient management.
- Promote the integration of research work and health care service delivery.

Conditions

- European and Developing Countries Clinical Trials Partnership (EDCTP) = focal point of clinical research cooperation on infectious disease between EU and sub-Saharan Africa
- Any poverty-related infectious disease (PRD) or group of PRDs affecting sub-Saharan Africa
- Combine health with mobile/digital or other technologies / big data processing.
- Networking with EDCTP projects

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

DISEASE-04-04: Clinical validation of artificial intelligence (AI) solutions for treatment and care

Scope (all of the following topics):

- Implementing **clinical studies** (based on existing (pre) clinical evidence) to validate AI-based solutions for more effective disease management
 - optimised personalised treatments & assessment of health outcomes
 - comparing benefits versus standard-of-care treatments (usability, performance, safety, clinical evaluation, (cost-) effectiveness, inclusion into current EU clinical guidelines for personalised treatments)
 - covering entire pathway for establishing SOPs for the integration of AI in health care (for clinical decision-making in treatment & care).
- Support clinical development, testing & validation of AI-assisted treatment and care options
 - Timely end-user inclusion (patient, caregiver, health care professional)
 - Assessing potential manual or automated biases for large uptake;
 - Measuring (cost-)effectiveness of AI-assisted development of therapeutic strategies and its implementation in clinical practice

Conditions

- Non-communicable diseases
- Multidisciplinary / Intersectoral approaches
- International collaboration for comprehensiveness and transferability of developed solutions.
- Plan for regulatory acceptability of their technologies
- SME(s) participation is encouraged.
- Aspects
 - Gender, Age, Socio-economic, Lifestyle

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

DISEASE-04-07: Personalised medicine + infectious diseases: understanding individual host response to viruses (e.g. SARS-CoV-2)

Scope (1 of the two topics):

- Characterization of host response and host-pathogen interaction to a virus (level: genetic, physiological, molecular):
 - Predisposition to clinical symptoms
 - Disease progression
 - Clinical outcome
- Deep **immunological phenotyping** of the host response,
 - use of animal models or in-vitro models
 - dynamics of innate / adaptive immune responses to the chosen virus(es) (immunity duration, effect of potential subsequent infections, etc.)
- Inform on
 - disease progression, development of personalised prophylactic and therapeutic strategies.

Conditions

- Networking with:
 - European COVID-19 data sharing platform
 - COVID-19 projects
 - ICPeMed
- Aspects:
 - Age, sex, gender,
 - Ethnicity
 - Chronic conditions
 - Co-morbidities
 - Treatments offered
- Representation across Europe

HORIZON EUROPE CLUSTER HEALTH

—

DESTINATION 4

Ensuring access to innovative, sustainable & high-quality healthcare

#CARE

HLTH-2021-CARE-05-01: Enhancing quality of care and patient safety

Scope (at least 3 of the following items BUT also additional items):

Harmonisation and standardisation of health care processes (Guidelines, SOPs) to improve quality and safety of health services & ensure the quality and comparability of health data

- Fill knowledge + practice gaps (decision-making processes across regions and countries).
- Develop + pilot uniform interventions in health care institutions of different EU regions / countries (case studies: hospital, primary+ outpatient care)
- Research on translation of international standards & clinical guidelines into national practice
- Facilitators + barriers for transferring good practices across EU
- Comparison of clinical guideline practices in EU
- Develop innovative approaches for integration of standardised practices.

Conditions

- In-hospital adverse effects:
 - surgical related,
 - medication or drug related,
 - health care associated infections
- Networking with EU-funded initiatives
- Patient-centred approaches
 - PROMs/PREMs - patient-reported outcome/experiences measures
- Aspects
 - Sex & Gender
- Unleash social innovation

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

HLTH-2021-CARE-05-02: Data-driven decision-support tools for better health care delivery and policy-making with a focus on cancer

Scope (1 or more of the following topics):

Developing tools/processes/services based on health care data optimising/transforming health care delivery decision-making, supporting policy-making, a/or citizens + cancer patients:

- Data-driven, interactive **policy & visualisation tools** (digital twins) bringing novel insights on populations/systems/services
- Data-driven **solutions** (scenario-building tools/models) helping health care organisations take evidence-informed decisions on cancer care delivery processes
- Data-driven **solutions** empowering citizens and cancer patients interaction with the health care systems (incl. feedback mechanisms, health care data management, ...)
- Digital **toolkits and indicators** to improve reporting / assessment of outputs from end-user involvements

Conditions

- Supporting Europe's Beating Cancer Plan
- Multi-disciplinary approach
 - Health care research
 - Health economics,
 - Implementation science,
 - Operations management
 - Data science
- Data-driven innovation
- 1 or more stages of disease:
 - Prevention
 - Early diagnosis
 - Treatment
 - Quality of life of patients
- Adopt international standards in computational models.

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

Mission Cancer: zusätzliches Arbeitsprogramm ab Q3/4

HORIZON EUROPE CLUSTER HEALTH

—

DESTINATION 5

Unlocking the full potential of new tools, technologies
and digital solutions for a healthy society

#TOOLS

TOOL-06-01: **Smart medical devices** and their surgical implantation for use in resource-constrained settings (IA)

Scope (1 of the two topics):

- “Smart” active implants = surgically-implanted medical devices equipped with micro-electronic sensor/actuator systems providing novel functionalities
- Challenges = miniaturization, sensor robustness, wireless power supply, surgical implantation procedures, activation
- Need = for high-quality, affordable surgical interventions for implanting “smart” active medical devices suitable for resource-limited or -constrained clinical settings (lack of medical staff, scarcity of medical equipment or medicines supply)
- R & I activities comprise: (1) medical device design, (2) regulatory work, (3) clinical stages and developmental iterations

Conditions

- **Start-TRL/End-TRL = 4 to 7**
- **Stakeholders** to involve: Medical specialists (e.g. surgeons), health care professionals, developers, patients, regulatory bodies
- Device targeted and intended use open (e.g. orthopaedic, neural, cardiovascular, metabolic)
- **Implantation** procedures compatible with resource-constrained + **minimally invasive approaches**
- Open for wide range of medical handicaps, complex chronic conditions + lesions with **unmet clinical needs**

TOOL-06-02: Next generation **advanced therapies** to treat highly prevalent and high burden diseases with unmet medical needs

Scope (1 of the following areas):

- **Adv. therapies: Pluripotent stem cells, gene editing or RNA**
- Supporting **preclinical research platforms** for disorders addressing critical parameters (safety, upscaling, immunity, potency assays, cost-effectiveness, and early on in development)
- **Area 1** - Method development for production + differentiation of **PSC**
- **Area 2** - Development + validation of biological assays / methods demonstrating efficacy, delivery, specificity, and safety (including off-target effects) of **genome editing** products in targeted cells (in vivo validation)
- **Area 3** - Development + validation of novel **RNA-based** therapeutics targeting noncommunicable diseases
- Study, analysis and tackling of different **immune responses** (sex and age dimension), generated by any of the above-mentioned advanced therapies **in vivo**, facilitating **regulatory approval** for next phase of research and development.

Conditions

- Disorders with high prevalence and burden and unmet needs
- Oviedo Convention conformity
- Range of actions: Assay development, modes of action, delivery, safety, in vivo validation, upscaling

TOOL-06-03: Innovative tools for use and re-use of **health data** (in part. of electronic health records and/or patient registries)

Scope (all of the following aspects):

- Developing robust **novel solutions** compliant with legal requirements to improve the quality, interoperability, machine-readability and re-use of health data and metadata
- Developing innovative natural language processing **tools**, (incl. computational semantics, ontologies, text mining, associated machine/deep learning) to improve accessibility, interoperability, translation, transcription & analysis of health data (e.g. to predict risks).
- Developing and piloting AI-powered **virtual assistants** that will utilise the tools and solutions developed (above) in order to demonstrate improved usability of health data for end-users.

Conditions

- Build on / contribute to existing European/Int'l data **standards** for health data, and research **infrastructure** efforts
- Focus on data in **electronic health records (HER)** from EU MS & EEA countries
- End-user involvement for adoption of developed solution (patient advocacy groups)
- Patient needs' **diversity**: gender, ethnicity, age, ability, socio-economic background,
- **SMEs** participation in consortium

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

HORIZON EUROPE CLUSTER HEALTH

—

DESTINATION 6

Maintaining an innovative, sustainable and globally competitive health industry

#IND

IND-07-01: Green pharmaceuticals

Scope (several of the following topics):

- R & I to support the **development** of “greener” pharmaceuticals that degrade more readily to harmless substances in wastewater treatment plants and the environment;
- R on **eco-toxicity** of pharmaceuticals (env. risk assessment)
- Proposal of **innovative manufacturing technology** that are greener, low in energy consumption and emissions, using less solvent or recycling solvents;
- Proposal of **methods** for eliminating carcinogenic impurities in pharmaceuticals (e.g. nitrosamines) process and medicinal products, in particular as complementary technologies to the manufacturing methods relying on recycled solvents;
- Exploration of **innovative uses of digital transformation** or robotic for competitive and **scalable methods of production**.

Conditions

- multi-stakeholders approach
 - industry incl. SMEs,
 - academia
 - public health
- gender dimension in R&I content is not a mandatory requirement.

HORIZON EUROPE CLUSTER HEALTH

Ausschreibungen

Projekttyp **Coordination & Support Actions**

Abgabetermin **2021/2022**

Informationen sind vorläufig und unverbindlich!!

Ausschreibungen |

CSA - 2021/2022

Call by Destination	Call No.	Type	Total Budget	No. of Projects	Deadline
Destination 1 – Staying healthy in a rapidly changing society					
Supporting digital empowerment and health literacy of citizens	HORIZON-HLTH-2021-STAYHLTH-01-03	CSA	3 M€	1	21.09.2021
A roadmap for personalised prevention	HORIZON-HLTH-2021-STAYHLTH-01-04	CSA	3 M€	1	21.09.2021
Mobilising a network of National Contact Points (NCPs) for the Health Cluster	HORIZON-HLTH-2021-STAYHLTH-01-05	CSA	3 M€	1	21.09.2021
Destination 3 – Tackling diseases & reducing disease burden					
A roadmap towards the creation of the European partnership on One Health antimicrobial resistance (OH AMR)	HORIZON-HLTH-2021-DISEASE-04-05	CSA	0.5 M€	1	21.09.2021
Building a European partnership for pandemic preparedness	HORIZON-HLTH-2021-DISEASE-04-06	CSA	2 M€	1	21.09.2021
Support for the functioning of the Global Research Collaboration for Infectious Disease Preparedness	HORIZON-HLTH-2022-DISEASE-07-01	CSA	2 M€	1	21.04.2022

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

Ausschreibungen |

CSA - 2021/2022

innovativ+international



Call by Destination	Call No.	Type	Total Budget	No. of Projects	Deadline
Destination 4 – Ensuring access to innovative, sustainable & high-quality Healthcare					
Health care innovation procurement network	HORIZON-HLTH-2021-CARE-05-04	CSA	5 M€	1	21.09.2021
Destination 6 – Maintaining an innovative, sustainable and globally competitive health industry					
Development, procurement and responsible management of new antimicrobials	HORIZON-HLTH-2021-IND-07-02	CSA	2 M€	1	21.09.2021
Promoting a trusted mHealth label in Europe: uptake of technical specifications for quality and reliability of health and wellness apps	HORIZON-HLTH-2021-IND-07-03	CSA	2 M€	1	21.09.2021
Setting up a European Smart Health Innovation Hub	HORIZON-HLTH-2022-IND-13-04	CSA	2 M€	1	21.04.2022
Setting up a European Electronic Health Record Exchange Format (EEHRxF) Ecosystem	HORIZON-HLTH-2022-IND-13-05	CSA	2 M€	1	21.04.2022

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

Steinbeis 2i GmbH ©

HORIZON EUROPE CLUSTER HEALTH

Ausschreibungen

Projekttypen Research & Innovation Actions, Pre-commercial procurement, and Co-fund Action

Abgabetermin 2022

Informationen sind vorläufig und unverbindlich!!

Call by Destination	Call No.	Type	Total Budget	No. of Projects	Deadline
Destination 1 – Staying healthy in a rapidly changing society					
Boosting mental Health in Europe in times of change	HORIZON-HLTH-2022-STAYHLTH-01-two-stage-01	RIA	50 M€	7	01.02.2022
Trustworthy artificial intelligence (AI) tools to predict the risk of chronic non-communicable diseases and/or their progression	HORIZON-HLTH-2022-STAYHLTH-01-two-stage-04	RIA	60 M€	10	01.02.2022
Prevention of obesity throughout the life course	HORIZON-HLTH-2022-STAYHLTH-01-05-two-stage	RIA	60 M€	6	01.02.2022
Personalised blueprint of chronic inflammation in health-to-disease transition	HORIZON-HLTH-2022-STAYHLTH-02-01	RIA	50 M€	7	21.04.2022

Ausschreibungen |

RIA – 2022

innovativ+international



Call by Destination	Call No.	Type	Total Budget	No. of Projects	Deadline
Destination 3 – Tackling diseases & reducing disease burden					
Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs	HORIZON-HLTH-2022-DISEASE-06-02-two-stage	RIA	60 M€	10	01.02.2022
Vaccines 2.0 - developing the next generation of vaccines	HORIZON-HLTH-2022-DISEASE-06-03-two-stage	RIA	40 M€	5	01.02.2022
Development of new effective therapies for rare diseases	HORIZON-HLTH-DISEASE-2022-06-two-stage-04	RIA	60 M€	8	01.02.2022
Pandemic preparedness - <i>Placeholder</i>	HORIZON-HLTH-2022-DISEASE-07-02	RIA	10 M€	3	21.04.2022
Non-communicable diseases risk reduction in adolescence and youth	HORIZON-HLTH-2022-DISEASE-07-03	RIA	25 M€	8	21.04.2022
European partnership fostering a European Research Area (ERA) for health research - <i>Placeholder</i>	HORIZON-HLTH-2022-DISEASE-03-01	Co-fund Action	30 M€	1	21.04.2022

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

Steinbeis 2i GmbH ©

Ausschreibungen |

RIA – 2022

Call by Destination	Call No.	Type	Total Budget	No. of Projects	Deadline
Destination 4 – Ensuring access to innovative, sustainable & high-quality Healthcare					
Pre-commercial research and innovation procurement (PCP) for building the resilience of health and care systems in the context of recovery	HORIZON-HLTH-2022-CARE-08-02	PCP ¹	25 M€	5	21.04.2022
Better economic foresight, financial planning, and procurement/contractual strategies for health systems	HORIZON-HLTH-2022-CARE-08-04	RIA	30 M€	6	21.04.2022
European partnership on transforming health and care systems	HORIZON-HLTH-2022-CARE-10-01	Co-fund Action	100 M€	1	21.04.2022
Destination 5 – Unlocking the full potential of new tools, technologies and digital solutions for a healthy society					
Optimising effectiveness in patients of existing prescription drugs for major diseases (except cancer) with the use of biomarkers	HORIZON-HLTH-2022-TOOL-11-01	RIA	60 M€	6	21.04.2022

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.

Ausschreibungen |

RIA – 2022

Call by Destination	Call No.	Type	Total Budget	No. of Projects	Deadline
New methods for the effective use of real-world data and/or synthetic data in regulatory decision-making and/or in health technology assessment Call - Tools and technologies for a healthy society (Two Stage - 2022)	HORIZON-HLTH-2022-TOOL-11-02	RIA	35 M€	5	21.04.2022
Computational models for new patient stratification strategies	HORIZON-HLTH-2022-TOOL-12-01-two-stage	RIA	60 M€	10	01.02.2022
Destination 6 – Maintaining an innovative, sustainable and globally competitive health industry					
Enhancing cybersecurity of connected medical devices	HORIZON-HLTH-2022-IND-13-01	RIA	20 M€	3	21.04.2022
Scaling up multi-party computation, data anonymisation techniques, and synthetic data generation	HORIZON-HLTH-2022-IND-13-02	RIA	30 M€	4	21.04.2022
New pricing and payment models for cost-effective and affordable health innovations	HORIZON-HLTH-2022-IND-13-03	RIA	15 M€	3	21.04.2022

Fragen können im Chat gestellt werden. Die Fragen und Antworten sowie diese Präsentation erhalten Sie anschließend.



Dr. Kristin Dallinger

kristin.dallinger@steinbeis-europa.de

Hicham Abghay

hicham.abghay@steinbeis-europa.de

www.steinbeis-europa.de